Allspring Global Investments Holdings LLC Sells 10,390 Shares of Sanofi $SNY

Allspring Global Investments Holdings LLC reduced its stake in shares of Sanofi (NASDAQ:SNY) by 7.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 121,032 shares of the company’s stock after selling 10,390 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Sanofi were worth $6,023,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Ameritas Advisory Services LLC bought a new position in Sanofi during the 2nd quarter worth approximately $28,000. Concord Wealth Partners raised its holdings in Sanofi by 510.3% in the second quarter. Concord Wealth Partners now owns 885 shares of the company’s stock worth $43,000 after purchasing an additional 740 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Sanofi by 233.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after purchasing an additional 700 shares in the last quarter. Traub Capital Management LLC acquired a new position in shares of Sanofi in the 2nd quarter valued at $51,000. Finally, Whittier Trust Co. grew its holdings in shares of Sanofi by 34.1% in the 2nd quarter. Whittier Trust Co. now owns 1,462 shares of the company’s stock valued at $71,000 after buying an additional 372 shares during the period. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Up 1.4%

NASDAQ:SNY opened at $48.17 on Wednesday. The stock has a 50-day simple moving average of $49.34 and a 200 day simple moving average of $48.87. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a market cap of $117.49 billion, a PE ratio of 11.28, a PEG ratio of 1.18 and a beta of 0.45. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $1.60 by $1.31. The firm had revenue of $15.46 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.25 EPS. On average, sell-side analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several research analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Barclays reaffirmed an “equal weight” rating on shares of Sanofi in a research report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.